Edgestream Partners L.P. Buys Shares of 15,100 Exact Sciences Co. (NASDAQ:EXAS)

Edgestream Partners L.P. bought a new stake in Exact Sciences Co. (NASDAQ:EXAS) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 15,100 shares of the medical research company’s stock, valued at approximately $1,418,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of EXAS. Park Place Capital Corp grew its position in Exact Sciences by 189.2% in the first quarter. Park Place Capital Corp now owns 376 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 246 shares during the last quarter. True Wealth Design LLC acquired a new stake in shares of Exact Sciences during the fourth quarter valued at about $30,000. TCI Wealth Advisors Inc. boosted its stake in shares of Exact Sciences by 15,466.7% during the first quarter. TCI Wealth Advisors Inc. now owns 467 shares of the medical research company’s stock valued at $32,000 after purchasing an additional 464 shares in the last quarter. Ameritas Advisory Services LLC acquired a new stake in shares of Exact Sciences during the first quarter valued at about $32,000. Finally, Money Concepts Capital Corp acquired a new stake in shares of Exact Sciences during the fourth quarter valued at about $36,000. Institutional investors own 89.13% of the company’s stock.

Exact Sciences Trading Up 1.5 %

Shares of Exact Sciences stock opened at $67.29 on Tuesday. The stock has a fifty day simple moving average of $66.20 and a 200 day simple moving average of $79.81. Exact Sciences Co. has a 12-month low of $40.73 and a 12-month high of $100.77. The company has a market capitalization of $12.17 billion, a P/E ratio of -42.32 and a beta of 1.46. The company has a current ratio of 2.41, a quick ratio of 2.13 and a debt-to-equity ratio of 0.74.

Insider Buying and Selling

In other Exact Sciences news, insider Everett Cunningham sold 13,007 shares of the business’s stock in a transaction on Thursday, October 12th. The stock was sold at an average price of $66.49, for a total value of $864,835.43. Following the transaction, the insider now owns 37,909 shares of the company’s stock, valued at $2,520,569.41. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 1.30% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

EXAS has been the topic of a number of recent analyst reports. Jefferies Financial Group lifted their price objective on Exact Sciences from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Piper Sandler lowered their target price on Exact Sciences from $90.00 to $80.00 and set an “overweight” rating for the company in a report on Monday, October 16th. Sanford C. Bernstein initiated coverage on Exact Sciences in a report on Thursday, September 28th. They set an “outperform” rating and a $83.00 price objective for the company. Benchmark downgraded Exact Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Finally, Bank of America boosted their price objective on Exact Sciences from $105.00 to $110.00 in a report on Wednesday, August 2nd. Five research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $96.56.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.